Search Results

You are looking at 1 - 10 of 14 items for :

  • Sitagliptin x
Clear All
Open access

E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis and K Kotsa

-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) inhibitor (sitagliptin) and cholecalciferol. Case presentation A 31-year-old Caucasian male was referred to

Open access

Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble and Constantin Polychronakos

been remitted for a year, being currently treated only with sitagliptin. Case presentation The case is a 19-year-old male patient from Ciudad Bolívar, Venezuela, without any familial history of diabetes, presented with polyuria, polydipsia, and

Open access

Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro and Margareth Afonso Torres

uncommon. In general terms, partial remission is defined as a daily requirement of insulin <0.5 IU/kg and levels of HbA1c <6% and stimulated C-peptide >0.90 ng/mL ( 4 , 5 ). Dipeptidyl peptidase 4 (DPP-4) inhibitors, such as sitagliptin, have been used

Open access

Jiman Kim, Eulsun Moon and Seungwon Kwon

January 2012 because of several hypoglycemic events and oral hypoglycemic therapy was resumed (sitagliptin 100 mg/day, metformin 500 mg/day). However, in November 2013, diabetic nephropathy corresponding to stage 3 chronic kidney disease (CKD) was detected

Open access

Murray B Gordon and Kellie L Spiller

period, the patient continued to take metformin 1000 mg b.i.d., while dosing of insulin varied due to changes in diet and exercise ( Table 1 ). At month 28, sitagliptin was added to the antidiabetic regimen, which was replaced by liraglutide at month 63

Open access

Rajesh Rajendran, Sarita Naik, Derek D Sandeman and Azraai B Nasruddin

glycaemic control and HbA1c increased from 58.5 mmol/mol (7.5%) to 79.2 mmol/mol (9.4%), within 2 months of pasireotide therapy. Following introduction of sitagliptin, this improved to 66 mmol/mol (8.2%). MRI of pituitary gland at 3 months showed change in

Open access

Elena Carrillo, Amparo Lomas, Pedro J Pinés and Cristina Lamas

. Glimepiride in monotherapy was initially prescribed, associating sitagliptin some time later. Following this treatment, the patient maintained his glycated hemoglobin around 6.5% for six years. After this period, there was a gradual deterioration of metabolic

Open access

Senhong Lee, Aparna Morgan, Sonali Shah and Peter R Ebeling

commenced empagliflozin 12.5 mg twice a day (BD) two days prior to his presentation as third-line agent for treatment of diabetes in addition to metformin 850 mg BD and sitagliptin 50 mg BD. A diagnosis of diabetic ketoacidosis (DKA) was made, and patient

Open access

Diana Catarino, Cristina Ribeiro, Leonor Gomes and Isabel Paiva

acyclovir for 10 days (1 g/day). The patient was discharged under hydrocortisone (10 mg at wake time and 5 mg in the afternoon), metformin/sitagliptin (1000 mg/50 mg, twice daily) and insulin glargine (5 units at night). There was progressive reduction in

Open access

Mohammed Faraz Rafey, Arslan Butt, Barry Coffey, Lisa Reddington, Aiden Devitt, David Lappin and Francis M Finucane

hypoglycaemia. His insulin was stopped and gliclazide MR 30 mg was started, with subsequent excellent glycaemic control. However, over the following 18 months he required an increased dose of gliclazide MR to 120 mg daily and the introduction of sitagliptin 100